Methadone is a synthetic opioid medication used to treat two distinct conditions: chronic pain and opioid use disorder (OUD). It works by activating the same receptors in the brain that other opioids target, but its unusually long duration of action, which can stretch well beyond 24 hours, makes it uniquely suited for stabilizing people who would otherwise cycle through withdrawal and craving throughout the day.
How Methadone Works in the Body
Methadone is a full agonist at the brain’s primary opioid receptors, meaning it fully activates them rather than partially stimulating them the way some other treatments do. These receptors sit in areas of the brain and spinal cord responsible for pain signaling, mood, and breathing. When methadone binds to them, it blocks pain transmission and reduces the intense cravings and withdrawal symptoms that drive continued opioid use.
What sets methadone apart from most opioids is a second mechanism: it also blocks a receptor involved in nerve-based pain signaling (called the NMDA receptor). This makes it particularly effective for certain types of chronic pain that don’t respond well to other painkillers, including nerve pain.
Methadone’s elimination half-life varies enormously from person to person, ranging from about 2 hours to nearly 50 hours depending on individual metabolism and other medications being taken. In most people, a single dose provides steady effects for 24 to 36 hours. This long action is what allows once-daily dosing and prevents the sharp highs and lows associated with shorter-acting opioids like heroin or oxycodone.
Treating Opioid Use Disorder
Methadone is the oldest and most studied medication for opioid use disorder. It works by occupying the same receptors that heroin or prescription opioids would, preventing withdrawal symptoms and reducing cravings without producing the euphoric rush that drives addiction. People on a stable methadone dose can function normally: working, driving, and maintaining relationships.
Treatment typically starts with a dose between 10 and 30 milligrams per day. Someone who has been actively using opioids may start at the higher end of that range, while someone who hasn’t used recently starts lower to avoid overdose. Over the following weeks, the dose is gradually increased. Most people stabilize on a maintenance dose between 60 and 120 milligrams per day, though some need more or less. Research consistently shows that doses above 60 milligrams are more effective at preventing relapse.
Compared to buprenorphine, the other main medication for OUD, methadone tends to keep people in treatment longer. One study tracking patients after hospital discharge found that 35% of those started on methadone remained in outpatient treatment at 12 weeks, compared to 13% of those started on buprenorphine. That gap was statistically significant. Staying in treatment matters because longer engagement dramatically reduces the risk of overdose death and relapse.
Methadone for Pain Management
Outside of addiction treatment, methadone is prescribed for chronic pain, especially when other opioids have stopped working or when nerve pain is a major component. Its dual mechanism (activating opioid receptors while blocking NMDA receptors) gives it an edge for complex pain conditions. It’s also significantly cheaper than many extended-release painkillers, which matters for patients on long-term therapy.
When prescribed for pain, methadone is dispensed through regular pharmacies with a standard prescription, unlike its use for OUD. The dosing schedule and amounts differ from addiction treatment, and the prescribing physician manages it like any other pain medication.
Side Effects and Cardiac Risk
The most common side effects of methadone resemble those of other opioids: constipation, sweating, drowsiness, nausea, and reduced sex drive. Most of these diminish over the first few weeks as the body adjusts, though constipation and sweating often persist.
The more serious concern is methadone’s effect on the heart’s electrical rhythm. It can lengthen a specific interval in the heartbeat cycle (the QT interval), and when that interval stretches too far, it raises the risk of a dangerous heart rhythm called Torsades de Pointes. Most people with a prolonged QT interval have no symptoms at all, but some experience palpitations, fainting, or seizures. The risk becomes significant when the QT interval exceeds 500 milliseconds on an EKG.
Federal guidelines recommend a baseline heart rhythm check for anyone with risk factors like a history of irregular heartbeat, fainting episodes, or family history of sudden cardiac death. Additional monitoring is advised when doses climb above 120 milligrams per day. If the QT interval crosses into the danger zone, providers typically lower the dose, switch to a different medication, or address other contributing factors like electrolyte imbalances.
Overdose Risk
Methadone overdose looks like any opioid overdose: slowed or stopped breathing, pinpoint pupils, and loss of consciousness. The critical difference is timing. Because methadone stays active in the body so much longer than other opioids, respiratory depression can develop hours after a dose and persist for an extended period. This is especially dangerous during the first weeks of treatment, before the body has fully adapted to the medication.
Even people on stable maintenance doses experience some degree of reduced breathing sensitivity, though their bodies compensate over time. The risk spikes when someone takes more than prescribed, combines methadone with sedatives like benzodiazepines or alcohol, or restarts treatment after a break (when tolerance has dropped). Naloxone, the standard opioid overdose reversal agent, works against methadone but may need to be given repeatedly because methadone outlasts it.
Drug Interactions
Methadone is broken down in the liver by several enzyme pathways, and many common medications can interfere with this process. Drugs that slow methadone’s metabolism, like certain antifungal medications and some antibiotics, cause methadone levels to build up in the blood, increasing the risk of side effects and overdose. Drugs that speed up metabolism, like some seizure medications and certain HIV treatments, can drop methadone levels low enough to trigger withdrawal symptoms.
This is one reason why anyone taking methadone needs their prescribers to know about every other medication they’re on, including over-the-counter drugs and supplements. Even grapefruit juice can affect methadone metabolism enough to matter.
How Treatment Access Works
For opioid use disorder, methadone can only be dispensed through federally certified opioid treatment programs (OTPs), commonly called methadone clinics. This is different from buprenorphine, which any qualified provider can prescribe from a regular office. The clinic model means patients initially visit daily for observed dosing.
Federal regulations updated in 2024 loosened take-home rules significantly. New patients can receive up to a 7-day take-home supply during their first two weeks of treatment. After 15 days, that extends to 14 days. After one month, patients can receive up to 28 days of take-home medication at once. These decisions are made by the clinic’s medical team based on the individual’s stability and progress. Clinics also provide take-home doses for weekends and holidays regardless of how long someone has been in treatment.
These changes represent a major shift from the previous system, which required months or even years of daily visits before earning significant take-home privileges. The updated rules aim to reduce barriers for people in rural areas, those with jobs that conflict with clinic hours, and anyone for whom daily visits create more problems than they solve.
Methadone During Pregnancy
Methadone has been the standard treatment for pregnant women with opioid use disorder for decades. Abruptly stopping opioids during pregnancy carries serious risks, including miscarriage and preterm labor, so maintenance treatment is strongly preferred. Methadone allows the pregnancy to progress more safely while keeping the mother stable.
The main concern is neonatal abstinence syndrome (NAS), a set of withdrawal symptoms in newborns. Published rates of NAS requiring medical treatment have historically ranged from 60% to 80%, but programs using careful dosing protocols have brought that number down to around 29%. Interestingly, the mother’s methadone dose does not predict whether her baby will develop NAS. Male infants appear more vulnerable, with treatment rates of 38% compared to 16% for female infants in one study.